Stockscreener 앱 받기
9.51
0.74%
0.07
시간 외 거래:
9.51
전일 마감가:
$9.44
열려 있는:
$9.54
하루 거래량:
2.87M
Relative Volume:
2.24
시가총액:
$830.67M
수익:
-
순이익/손실:
$-185.15M
주가수익비율:
-4.6956
EPS:
-2.0253
순현금흐름:
$-148.72M
1주 성능:
-2.46%
1개월 성능:
-26.28%
6개월 성능:
-69.13%
1년 성능:
+131.95%
1일 변동 폭
$9.06
$9.8299
1주일 범위
$9.06
$10.09
52주 변동 폭
$4.02
$36.26
올레마 Stock (OLMA) Company Profile
명칭
Olema Pharmaceuticals Inc
전화
(415) 651-3316
주소
780 BRANNAN STREET, SAN FRANCISCO
Compare OLMA vs VRTX, REGN, ARGX, ALNY, RVMD
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
OLMA
Olema Pharmaceuticals Inc
|
9.51 | 830.67M | 0 | -185.15M | -148.72M | -2.0253 |
VRTX
Vertex Pharmaceuticals Inc
|
451.63 | 114.63B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
609.94 | 63.95B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
877.72 | 54.58B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
278.09 | 37.13B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
162.99 | 34.65B | 742.00K | -1.37B | -1.07B | -7.0731 |
올레마 Stock (OLMA) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2026-03-27 | 개시 | Wolfe Research | Peer Perform |
| 2026-03-19 | 재개 | Jefferies | Buy |
| 2026-02-11 | 개시 | Stifel | Buy |
| 2026-01-07 | 개시 | Piper Sandler | Overweight |
| 2025-10-08 | 개시 | Guggenheim | Buy |
| 2025-08-12 | 재확인 | Citigroup | Buy |
| 2024-04-02 | 개시 | Goldman | Buy |
| 2024-01-30 | 개시 | Citigroup | Buy |
| 2023-07-21 | 개시 | Oppenheimer | Outperform |
| 2023-05-05 | 개시 | CapitalOne | Overweight |
| 2023-02-22 | 개시 | Credit Suisse | Outperform |
| 2022-07-06 | 재개 | Canaccord Genuity | Buy |
| 2022-06-09 | 업그레이드 | H.C. Wainwright | Neutral → Buy |
| 2022-02-28 | 개시 | H.C. Wainwright | Neutral |
| 2021-12-07 | 재개 | Cowen | Outperform |
| 2020-12-14 | 개시 | Canaccord Genuity | Buy |
| 2020-12-14 | 개시 | Cowen | Outperform |
| 2020-12-14 | 개시 | JP Morgan | Overweight |
| 2020-12-14 | 개시 | Jefferies | Buy |
모두보기
올레마 주식(OLMA)의 최신 뉴스
Olema Pharmaceuticals | S-8: Initial registration statement for securities to be offered to employees pursuant to employee benefit plansmoomoo - Moomoo
Olema Pharmaceuticals Inc (OLMA) Institutional Confidence - TradingKey
Olema Pharmaceuticals Inc (OLMA) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
Olema Pharmaceuticals Inc (OLMA) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
Olema Pharmaceuticals Inc (OLMA) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
Olema Pharmaceuticals Inc (OLMA) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
Olema Pharmaceuticals Inc (OLMA) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
How Olema Pharmaceuticals (OLMA) Is Adding Pipeline Depth Behind Its Palazestrant Breast Cancer Bet - Yahoo Finance
Olema Pharmaceuticals Inc (OLMA) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
OLMA News | OLEMA PHARMACEUTICALS INC (NASDAQ:OLMA) - ChartMill
OLMA Stock Soars 47% in September So Far on Second PFE Deal - MSN
OLMA,GH Options - Finviz
Olema Pharmaceuticals Inc at Goldman Sachs Healthcare Conference Transcript - GuruFocus
J.P. Morgan Maintains Olema Pharmaceuticals(OLMA.US) With Buy Rating - Moomoo
InvestingPro’s Fair Value flagged Olema stock as overvalued at $19.49 By Investing.com - Investing.com Canada
OLMA Q1 2026 Earnings: Narrower-Than-Expected Loss as Biotech Advances PipelineNegative Surprise Momentum - newsline.com
LifeSci Capital Maintains Olema Pharmaceuticals(OLMA.US) With Buy Rating, Maintains Target Price $24 - Moomoo
UBS Remains a Buy on Olema Pharmaceuticals (OLMA) - The Globe and Mail
OLMA Technical Analysis | Trend, Signals & Chart Patterns | OLEMA PHARMACEUTICALS INC (NASDAQ:OLMA) - ChartMill
LifeSci Capital Maintains Olema Pharmaceuticals(OLMA.US) With Buy Rating, Cuts Target Price to $24 - Moomoo
Olema Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - The Manila Times
Why Olema Pharmaceuticals (OLMA) Is Down 7.1% After Bayer OP-3136 Prostate Cancer Trial Deal And Data - Sahm
Guggenheim Maintains Olema Pharmaceuticals(OLMA.US) With Buy Rating, Cuts Target Price to $35 - Moomoo
OLMA Stock Price, Quote & Chart | OLEMA PHARMACEUTICALS INC (NASDAQ:OLMA) - ChartMill
Olema Pharmaceuticals Inc. (OLMA) Q1 2026 Earnings: Narrower-Than-Expected Loss Amid Ongoing Clinical Progress - thelegaladvocate.com
Olema Pharmaceuticals, Bayer Collaborate to Test Potential Prostate Cancer Combination Therapy - Moomoo
H.C. Wainwright Maintains Olema Pharmaceuticals(OLMA.US) With Buy Rating, Maintains Target Price $38 - Moomoo
Olema Pharmaceuticals (OLMA) Teams Up with Bayer for Clinical Tr - GuruFocus
Olema Oncology inks clinical trial collaboration with Bayer - The Pharma Letter
Olema Oncology and Bayer Partner on Clinical Trial to Evaluate OP-3136 and NUBEQA® in Metastatic Castration-Resistant Prostate Cancer 1 - Minichart
Olema Pharmaceuticals (OLMA) Teams Up with Bayer for Clinical Trial - GuruFocus
Olema Oncology Announces Clinical Trial Collaboration and Supply Agreement with Bayer to Evaluate OP-3136 in Combination with NUBEQA® (darolutamide) in Metastatic Castration-Resistant Prostate Cancer - The Manila Times
Olema oncology announces clinical trial collaboration and supply agreement with Bayer to evaluate OP-3136 in combination with Nubeqa® (darolutamide) in metastatic castration-resistant prostate cancer - marketscreener.com
Olema Oncology (NASDAQ: OLMA) inks Bayer trial deal for OP-3136 combo - Stock Titan
New prostate cancer trial pairs Olema drug with Bayer’s NUBEQA - Stock Titan
Olema’s OP-3136 Data Draw Focus To Oncology Pipeline And Valuation Gap - Yahoo Finance
OLMA Sees Early Tumor Shrinkage in Phase 1 OP-3136 Study, Stock Gains Pre-Market - Stocktwits
Analysts Offer Insights on Healthcare Companies: IN8bio (INAB), Syndax Pharmaceuticals (SNDX) and Olema Pharmaceuticals (OLMA) - The Globe and Mail
Olema Oncology sees early hope as cancer drug shows tumor shrinkage in phase 1 study - MSN
Olema Pharmaceuticals Analyst Ratings and Price Targets | NASDAQ:OLMA - Benzinga
Olema Oncology Sees Early Hope As Cancer Drug Shows Tumor Shrinkage In Phase 1 Study - Yahoo Finance
H.C. Wainwright reiterates Olema Pharmaceuticals stock rating at buy - Investing.com
H.C. Wainwright reiterates Olema Pharmaceuticals stock rating at buy By Investing.com - Investing.com Canada
Olema Oncology Reports Promising Phase 1 Results for OP-3136 KAT6 Inhibitor in Advanced Solid Tumors at 2026 ASCO Meeting 12 - Minichart
Olema reports phase 1 data for cancer drug OP-3136 By Investing.com - Investing.com South Africa
Olema reports phase 1 data for cancer drug OP-3136 - Investing.com UK
Olema Pharmaceuticals Reports Promising Initial Data for OP-3136 in Phase 1 Study Evaluating KAT6 Inhibitor for Advanced Solid Tumors - Quiver Quantitative
Olema Oncology (NASDAQ: OLMA) shares early OP-3136 Phase 1 cancer data - Stock Titan
Olema Oncology Announces Encouraging Initial Clinical Data - GlobeNewswire
ESR1-Mutated Metastatic Breast Cancer Market Expected to Grow Rapidly at 9.6% CAGR During the Forecast Period (2026–2036) Due to the Emergence of Novel Oral SERDs and Targeted Agents | DelveInsight - GlobeNewswire Inc.
Olema Oncology to Participate in Upcoming Investor Conferences - The Manila Times
올레마 (OLMA) 재무 분석
매출
순이익
현금흐름
주당 순 이익
0.74%
1.44%
자본화:
|
볼륨(24시간):